Takeda sells products worth $825 million in Latin America

Japanese pharma giant Takeda Pharmaceutical (TYO: 4502) is selling off $825 million worth of products in Latin America, part of the firm’s ultimate goal to divest non-core assets to the value of $10 billion.

Brazil’s largest drugmaker Hypera has agreed to buy the portfolio, which includes over-the-counter and prescription pharmaceutical products sold in Brazil, Mexico, Argentina, Colombia, Ecuador, Panama and Peru.

Hypera, which has a leading position in branded prescriptions, consumer health and branded generics in the region, will gain products which generated revenues of approximately $215 million in 2018.